• Procedure started
  • Under evaluation
  • CVMP opinion
  • European Commission final decision

Overview

Combisyn Lactating Cow Intramammary Suspension (Combisyn) is an intramammary suspension containing amoxicillin, clavulanic acid and prednisolone. Combisyn is intended for the treatment of mastitis in lactating cows.

The marketing authorisation holder, Norbrook Laboratories Ltd, submitted an application for Combisyn via a mutual recognition procedure in Austria, Belgium, Denmark, Finland, France, Portugal and Spain on the basis of the marketing authorisation granted by the United Kingdom. The application was submitted as a generic of the reference product, Synulox Lactating Cow Intramammary Suspension marketed by Pfizer Ltd. The mutual recognition procedure (UK/V/0356/001/MR) started on 26 November 2009.

On 2 July 2010, the United Kingdom, as Reference Member State, referred the matter to the European Medicines Agency under Article 33(4) of Directive 2001/82/EC, due to concerns raised by a Concerned Member States, France, that the safety and efficacy of the product had not been sufficiently demonstrated. There was disagreement between the Reference Member State and the Concerned Member States on the demonstration of bioequivalence and the adequacy of the proposed withdrawal period.

The referral procedure started on 14 July 2010. The Committee appointed Mr Johan Schefferlie as rapporteur and Mrs Ruth Kearsley as co-rapporteur. Further to the resignation of Mrs Ruth Kearsley as CVMP member, Ms Helen Jukes was appointed to replace her and took over the co-rapporteurship.

Written explanations were provided by the marketing authorisation holder on 13 September 2011 and 10 March 2011. Oral explanations were given on 12 January 2011.

Based on the evaluation of the rapporteur's assessment of the currently available data, the CVMP considered that the benefit/risk profile of Combisyn Lactating Cow Intramammary Suspension is negative, and therefore adopted an opinion on 6 April 2011 recommending the refusal of the granting of the marketing authorisations and suspension of the existing marketing authorisation.

Nine CVMP members expressed divergent positions, which are appended to the opinion.

The list of product names concerned is given in Annex I. The scientific conclusions and the grounds for refusal of the granting of the marketing authorisation and suspension of the existing marketing authorisation are provided in Annex II. The grounds for the lifting of the suspension of the marketing authorisation are provided in Annex III.

The final opinion was converted into a Decision by the European Commission on 5 August 2011.

български (BG) (139.19 KB - PDF)

View

español (ES) (121.02 KB - PDF)

View

čeština (CS) (121.62 KB - PDF)

View

dansk (DA) (122.22 KB - PDF)

View

Deutsch (DE) (121.81 KB - PDF)

View

eesti keel (ET) (118.67 KB - PDF)

View

ελληνικά (EL) (129.66 KB - PDF)

View

français (FR) (121.37 KB - PDF)

View

italiano (IT) (120.22 KB - PDF)

View

latviešu valoda (LV) (136.31 KB - PDF)

View

lietuvių kalba (LT) (122.29 KB - PDF)

View

magyar (HU) (122.27 KB - PDF)

View

Malti (MT) (136.66 KB - PDF)

View

Nederlands (NL) (121.4 KB - PDF)

View

polski (PL) (89.39 KB - PDF)

View

português (PT) (64.85 KB - PDF)

View

română (RO) (88.17 KB - PDF)

View

slovenčina (SK) (147.89 KB - PDF)

View

slovenščina (SL) (86.82 KB - PDF)

View

Suomi (FI) (125.1 KB - PDF)

View

svenska (SV) (124.93 KB - PDF)

View

Key facts

About this medicine

Approved name
Combisyn Lactating Cow
International non-proprietary name (INN) or common name
  • amoxicillin
  • clavulanic acid
  • Prednisolone
Associated names
Combisyn Lactating Cow

About this procedure

Current status
European Commission final decision
Reference number
EMA/V/A/063
Type
Article 33

Mutual-recognition and decentralised referral: initiated because of disagreement between Member States within the framework of the mutual-recognition or decentralised procedure.

Key dates and outcomes

Opinion date
06/04/2011
EC decision date
05/08/2011

All documents

български (BG) (88.09 KB - PDF)

View

español (ES) (82.29 KB - PDF)

View

čeština (CS) (80.31 KB - PDF)

View

dansk (DA) (87.83 KB - PDF)

View

Deutsch (DE) (83.34 KB - PDF)

View

eesti keel (ET) (82.33 KB - PDF)

View

ελληνικά (EL) (101.43 KB - PDF)

View

français (FR) (85.49 KB - PDF)

View

italiano (IT) (75.88 KB - PDF)

View

latviešu valoda (LV) (85.2 KB - PDF)

View

lietuvių kalba (LT) (80.84 KB - PDF)

View

magyar (HU) (84.36 KB - PDF)

View

Malti (MT) (90.21 KB - PDF)

View

Nederlands (NL) (86.75 KB - PDF)

View

polski (PL) (79.77 KB - PDF)

View

português (PT) (85.26 KB - PDF)

View

română (RO) (87.5 KB - PDF)

View

slovenčina (SK) (92.29 KB - PDF)

View

slovenščina (SL) (90.1 KB - PDF)

View

Suomi (FI) (76.19 KB - PDF)

View

svenska (SV) (75.88 KB - PDF)

View

български (BG) (139.19 KB - PDF)

View

español (ES) (121.02 KB - PDF)

View

čeština (CS) (121.62 KB - PDF)

View

dansk (DA) (122.22 KB - PDF)

View

Deutsch (DE) (121.81 KB - PDF)

View

eesti keel (ET) (118.67 KB - PDF)

View

ελληνικά (EL) (129.66 KB - PDF)

View

français (FR) (121.37 KB - PDF)

View

italiano (IT) (120.22 KB - PDF)

View

latviešu valoda (LV) (136.31 KB - PDF)

View

lietuvių kalba (LT) (122.29 KB - PDF)

View

magyar (HU) (122.27 KB - PDF)

View

Malti (MT) (136.66 KB - PDF)

View

Nederlands (NL) (121.4 KB - PDF)

View

polski (PL) (89.39 KB - PDF)

View

português (PT) (64.85 KB - PDF)

View

română (RO) (88.17 KB - PDF)

View

slovenčina (SK) (147.89 KB - PDF)

View

slovenščina (SL) (86.82 KB - PDF)

View

Suomi (FI) (125.1 KB - PDF)

View

svenska (SV) (124.93 KB - PDF)

View

Description of documents published

Please note that some of the listed documents apply only to certain procedures.

  • Overview - lay-language summary of the stage of the procedure
  • Notification – a letter from a Member State, the European Commission or the marketing authorisation holder requesting the initiation of the procedure
  • List of questions – questions agreed by the Committee requesting further information from the marketing authorisation holder(s) / applicant(s) to evaluate the issues identified
  • Timetable for the procedure – agreed timeframe to respond to the list of questions, to assess the issues and to adopt a conclusion
  • List of medicines concerned by the procedure – medicine(s) / active substance(s) concerned, and marketing authorisation holder(s) / applicant(s)
  • List of questions to be addressed by the stakeholders – call for data to be submitted by stakeholders (e.g. veterinary healthcare professionals, farmers, academia) (if applicable)
  • Stakeholder submission form – form to be used by stakeholders to submit data (if applicable)
  • Scientific conclusions – scientific conclusions of CVMP
  • Divergent positions – divergent positions of the CVMP members (if applicable)
  • Changes to the summary of product characteristics, labelling and package leaflet (amended sections or fully revised version) (if applicable)
  • Condition(s) to the marketing authorisation(s) – condition(s) for the safe and effective use of the medicine(s) (if applicable)
  • Condition for lifting the suspension – condition to be fulfilled for the suspension of the marketing authorisation(s) to be lifted (if applicable)

Topics

Share this page